Arch Biopartners Inc.

65 articles with Arch Biopartners Inc.

• Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

  3/23/2023

  Today, Arch Biopartners Inc. announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) program.

• Shares for Interest Debt Settlement; Grants Options

  12/15/2022

  Arch Biopartners Inc., announced that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements.

• Arch Biopartners Adds Farris Smith as a Strategic Advisor

  10/5/2022

  , Arch Biopartners Inc., a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith of Novo Nordisk Canada Inc as a Strategic Advisor for general corporate activity and business development of the Company’s drug candidates.

• Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

  8/5/2022

  Arch Biopartners Inc. announced today that the Company has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the Company’s drug candidates.

• Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

  2/14/2022

  Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced that Health Canada has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide in a new dosing arm of the trial.

• Shares for Interest Debt Settlement

  2/9/2022

  Arch Biopartners Inc., announced that the Company has arranged a shares for debt transaction to settle an aggregate of $424,767.07 in interest accrued up to December 31, 2021 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements.

• Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

  2/3/2022

  Arch Biopartners Inc. announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal Science Advances describing the mechanism of action for dipeptidase-1 (DPEP-1) in acute kidney injury (AKI).

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

  1/4/2022

  Arch Biopartners Inc. announced today that the Research Ethics Board at the Sunnybrook Research Institue has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide (LSALT and “Metablok”) in a new arm of the CATCO human trial.

• 

  Clinical Catch-Up: November 29-December 3

  12/6/2021

  Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.

• Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

  12/1/2021

  Arch Biopartners Inc.  announced today that its lead drug candidate, LSALT Peptide (LSALT and “Metablok”) will enter the Canadian Treatments for COVID-19.

• Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

  8/5/2021

  Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide is ongoing and will be disclosed to the public following third-party, scientific peer review.

• Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

  7/14/2021

  Arch Biopartners Inc. announced that Arch scientists have been awarded a Canadian Institutes of Health Research Team Grant worth $750,000 to study the potential benefit for the LSALT peptide to prevent inflammation in chronic kidney and lung diseases.

• Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

  6/10/2021

  Arch Biopartners Inc. announced today it has filed a new provisional patent application with the U.S. Patent and Trademark Office to protect new antibody drug candidates that target inflammation in the lungs, liver and kidneys mediated by dipeptidase-1 (DPEP-1).

• Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

  5/4/2021

  Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced it has completed enrollment for its Phase II study of Metablok, targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.

• Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury

  4/15/2021

  Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain (“Telara”) to clinically develop and market cilastatin, a small-molecule drug candidate for the treatment and prevention of acute kidney injury (“AKI”).

• Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide

  3/30/2021

  Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry of Health, Pharmaceuticals and Medical Devices Agency (MoH) to recruit up to twenty additional patients into the Phase II trial of its lead drug LSALT peptide (Metablok), targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.

• Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment

  3/24/2021

  Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive agreement with the University of Cincinnati (UC) to license new patent claims for an AB569 topical wound application designed to prevent, treat and heal burn/blast wound infections.

• Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

  3/16/2021

  Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for preventing organ inflammation, announced today that Health Canada has provided a No Objection Letter for the Company’s protocol amendments for the Phase II trial of its lead drug LSALT peptide (Metablok)

• ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

  3/4/2021

  Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett, Professor at the University of Cincinnati College of Medicine, published a paper entitled “AB569, A Non-toxic Combination of Acidified Nitrite and EDTA, is Effective at Killing the Notorious Iraq/Afghanistan Combat Wound Pathogens,